Exelixis, Inc. (NASDAQ:EXEL) VP Patrick J. Haley sold 1,000 shares of the company’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $18.84, for a total transaction of $18,840.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Patrick J. Haley also recently made the following trade(s):

  • On Monday, August 12th, Patrick J. Haley sold 1,000 shares of Exelixis stock. The shares were sold at an average price of $20.39, for a total transaction of $20,390.00.
  • On Tuesday, August 6th, Patrick J. Haley sold 25,000 shares of Exelixis stock. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00.
  • On Wednesday, July 10th, Patrick J. Haley sold 1,000 shares of Exelixis stock. The shares were sold at an average price of $20.96, for a total transaction of $20,960.00.

Shares of EXEL stock traded down $0.15 during trading hours on Thursday, hitting $19.26. The company’s stock had a trading volume of 1,577,632 shares, compared to its average volume of 3,178,453. The business has a fifty day moving average of $20.28 and a 200-day moving average of $21.26. The stock has a market cap of $5.83 billion, a price-to-earnings ratio of 13.47 and a beta of 2.04. Exelixis, Inc. has a twelve month low of $13.42 and a twelve month high of $25.31. The company has a current ratio of 8.64, a quick ratio of 8.53 and a debt-to-equity ratio of 0.02.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Wednesday, July 31st. The biotechnology company reported $0.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.23 by $0.02. Exelixis had a net margin of 70.52% and a return on equity of 31.31%. The firm had revenue of $240.28 million for the quarter, compared to analyst estimates of $226.97 million. During the same quarter last year, the business earned $0.31 earnings per share. Exelixis’s revenue was up 29.1% compared to the same quarter last year. On average, equities analysts expect that Exelixis, Inc. will post 0.92 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Financial Gravity Wealth Inc. boosted its position in Exelixis by 120,100.0% during the second quarter. Financial Gravity Wealth Inc. now owns 1,202 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 1,201 shares during the last quarter. Icon Wealth Partners LLC acquired a new stake in Exelixis during the first quarter worth approximately $27,000. Bessemer Group Inc. acquired a new stake in Exelixis during the second quarter worth approximately $28,000. Ibex Wealth Advisors acquired a new stake in Exelixis during the second quarter worth approximately $43,000. Finally, Signaturefd LLC boosted its position in Exelixis by 999.5% during the second quarter. Signaturefd LLC now owns 2,287 shares of the biotechnology company’s stock worth $49,000 after acquiring an additional 2,079 shares during the last quarter. Hedge funds and other institutional investors own 77.41% of the company’s stock.

Several research firms have recently commented on EXEL. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research report on Tuesday, August 6th. ValuEngine lowered shares of Exelixis from a “hold” rating to a “sell” rating in a research report on Wednesday, July 24th. Cowen set a $25.00 price target on shares of Exelixis and gave the company a “buy” rating in a research report on Wednesday, July 31st. BidaskClub lowered shares of Exelixis from a “hold” rating to a “sell” rating in a research report on Wednesday, August 28th. Finally, Stifel Nicolaus increased their price target on shares of Exelixis from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, August 1st. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the stock. Exelixis presently has a consensus rating of “Hold” and a consensus price target of $27.75.

About Exelixis

Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Read More: Management Fee

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.